9342-8530 Quebec Inc DGCRF

going, going, gone

[ready2go1]

Well, from the studies I have been reading over the weekend and the few releases that came out on Friday, my feeling is that its just a matter of time before Diagnocure is acquired. The physicians that deal with prostate cancer and psa are looking for an answer to help solve their problems of determining, what to do next? Now, with the risk of infection with prostate biopsies being talked about, there is even more of a reason why pca3 will be quickly adopted by physicians and patients. I can't imagine GPRO will acquire until they see what the bids look like for there company, but I would expect that whoever acquires GPRO, you will see them grab Diagnocure very quickly after. Test has been around 10 years and will go from $10 million to $100 million in a blink of an eye. My concern continues to be that someone could pull the trigger before FDA approval and before we at least make our initial run.
     I am also thinking that they are close to a partner for the Philly lab and maybe the news release on Friday was the warm up for whats coming. If this is the case, we will at least make a push towards $2.00. With any news of a panel meeting we will hit that right away and FDA approval could take us over $4.00. My question is all a matter of timing and we need to get out of this pit so that we are able to get acquired for a price that will make us all happy. Any ways, its coming.